<DOC>
	<DOCNO>NCT00266903</DOCNO>
	<brief_summary>Review outcome treatment endothelin receptor antagonist ( bosentan sitaxsetan ) alone combination Sildenafil ( PDE-5 inhibitor ) adult patient pulmonary hypertension due congenital heart disease .</brief_summary>
	<brief_title>Eisenmenger 's Syndrome Adults With CHD</brief_title>
	<detailed_description>The primary objective study examine medical record patient Eisenmenger 's Syndrome order determine effect endothelin receptor antagonist , alone combination , Sildenafil , symptom pulmonary hypertension . This review conduct Standard Care procedures New York Heart Association ( NYHA ) classification , six-minute walk exercise capacity , pulmonary pressure oxygens saturation . Pulmonary pressure determine echo cardiac catheterization analyze available . We hypothesize patient congenital heart defect develop ES improve six-minute walk distance , improve pulmonary arterial pressure improve oxygenation treatment endothelin receptor antagonists pulmonary vasodilator .</detailed_description>
	<mesh_term>Eisenmenger Complex</mesh_term>
	<criteria>Congenital heart disease ( unoperated , palliated repair ) Eisenmenger 's syndrome Age 18 80 Those meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>adult</keyword>
	<keyword>congenital heart disease</keyword>
	<keyword>Eisenmenger 's Syndrome</keyword>
	<keyword>Bosentan</keyword>
	<keyword>Sitaxsetan</keyword>
	<keyword>Sildenafil</keyword>
</DOC>